ADB-FUBINACA

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide

Aliases.ADB-F · AB-FUB-ADAMINA (incorrect)

A 2009 Pfizer patent diverted. Linked to hundreds of overdoses (United States, Russia 2014-2017).

Updated on 1 May 2026

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Identifiers

Formula: C₂₁H₂₃FN₄O₂
Molar mass: 382.40 g·mol⁻¹
CAS: 1445583-51-6
PubChem CID: 70969086
First described: 2009
Origin: Pfizer patent WO 2009/106980 (never marketed)
InChIKey: ZSSGCSINPVBLQD-UHFFFAOYSA-N

In plain terms

ADB-FUBINACA is a synthetic cannabinoid initially developed by a pharmaceutical company, then diverted towards the illicit market. Several waves of mass overdoses are attributed to it.

Receptors and activity

CB1
EC50 ≈ 0,17 nMAgonist
CB2
Agonist

Agonist
Partial agonist
Antagonist
Modulator
Inverse agonist

Hover over a row for the precise value (Ki, EC50…)

Subjective signature

Hover over an axis to read its definition.

Calm
20
Clarity
15
Sleep
55
Appetite
45
High
99

Editorial estimate, not clinical.

Pharmacology

ADB-FUBINACA belongs to Pfizer patent WO 2009/106980 (Buchler et al., 2009) - an abandoned analgesic programme. Diverted towards the illicit market around 2013. Characterisation by Banister et al. (ACS Chem Neurosci 2015, PMID 25714476): CB1 EC50 ≈ 0.17 nM (β-arrestin) - one of the most potent SCRAs documented. Multiple waves of overdoses: Mississippi 2015 (n ≈ 1000 cases), Florida 2017, several regions of Russia. France: listed by name by the **decree of 5 August 2013** (NOR AFSP1318894A; JORFTEXT000027822624). EU: Delegated (EU) **2019/369**.

Key sources.